Anti-hypercalcemic effect of orally administered recombinant Saccharomyces cerevisiae expressing salmon calcitonin on hypercalcemic rats.

Show simple item record

dc.contributor.author Sun, P.
dc.contributor.author Zhang, X.
dc.contributor.author Zang, X.
dc.contributor.author Zhou, X.
dc.contributor.author Chen, Y.
dc.contributor.author Arunakumara, K.K.I.U.
dc.contributor.author Liang, B.
dc.date.accessioned 2023-02-24T07:42:05Z
dc.date.available 2023-02-24T07:42:05Z
dc.date.issued 2007
dc.identifier.citation Sun, P., Zhang, X., Zang, X., Zhou, X., Chen, Y., Arunakumara, K. K. I. U. & Liang, B., (2007). Anti-hypercalcemic effect of orally administered recombinant Saccharomyces cerevisiae expressing salmon calcitonin on hypercalcemic rats. Biotechnology letters, 29(7), 1013-1018. https://doi.org/10.1007/s10529-007-9352-3. en_US
dc.identifier.issn 15736776
dc.identifier.uri http://ir.lib.ruh.ac.lk/xmlui/handle/iruor/11491
dc.description.abstract Oral delivery of salmon calcitonin (sCT) to rats via a recombinant Saccharomyces cerevisiae was assessed. A synthetic sCT gene was cloned and expressed in S. cerevisiae yAGA2- sCT. Recombinant salmon calcitonin (rsCT) expression was detected by flow cytometry. The resorption activity of osteoclasts was inhibited by 3 · 10–6 M rsCT. Oral administration of 5 g lyophilized yAGA2-sCT/kg to hypercalcemic rats decreased serum calcium from 2.8 ± 0.02– 2.7 ± 0.02 mM en_US
dc.language.iso en en_US
dc.publisher Springer en_US
dc.subject Hypercalcemia en_US
dc.subject Osteoclast en_US
dc.subject Saccharomyces cerevisia en_US
dc.subject Salmon calcitonin en_US
dc.title Anti-hypercalcemic effect of orally administered recombinant Saccharomyces cerevisiae expressing salmon calcitonin on hypercalcemic rats. en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account